Methyldopa 250mg tablets

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Methyldopa (anhydrous)

Pieejams no:

Bristol Laboratories Ltd

ATĶ kods:

C02AB01

SNN (starptautisko nepatentēto nosaukumu):

Methyldopa (anhydrous)

Deva:

250mg

Zāļu forma:

Oral tablet

Ievadīšanas:

Oral

Klase:

No Controlled Drug Status

Receptes veids:

Valid as a prescribable product

Produktu pārskats:

BNF: 02050200; GTIN: 5060013944161

Lietošanas instrukcija

Package leaflet: Information for the user
METHYLDOPA 250MG AND 500MG TABLETS
Read all of this leaflet carefully before you start taking this
medicine because it contains important information for you.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their
signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor, or pharmacist or
nurse. This includes any possible side effects not listed in this
leaflet.
See section 4.
What is in this leaflet:
1. What Methyldopa Tablets are and what they are used for
2. What you need to know before you take Methyldopa Tablets
3. How to take Methyldopa Tablets
4. Possible side effects
5. How to store Methyldopa Tablets
6. Contents of the pack and other information
30 mm
420 mm
180 mm
IXXXXXX
1. What Methyldopa Tablets are and what
they are used for
The name of your medicine is Methyldopa 250mg or 500mg
Tablets. It contains the active ingredient called methyldopa.
Methyldopa belongs to a group of medicines called
antihypertensives, which lower blood pressure. Methyldopa
tablets are used to treat high blood pressure (hypertension). It
works by relaxing the blood vessels so that blood can flow more
easily through the body.
2. What you need to know before you take
Methyldopa Tablets
Do not take Methyldopa Tablets if you:
•
are allergic to methyldopa or any of the other ingredients of
this medicine (listed in section 6)
•
have liver disease
•
suffer from depression
•
are taking MAOIs (monoamine oxidase inhibitors) for
depression.
•
have high blood pressure due to a tumour near your
kidney called ‘phaeochromocytoma’ or ‘paraganglioma’
•
have porphyria (a rare, inherited blood disorder)
Do not take Methyldopa if any of the above applies to you. If you
are not sure talk to your doctor or pharmacist before taking
Methyldopa.
Warnings and precautions:
Talk
to

Produkta apraksts

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Methyldopa 250mg Tablets BP
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Tablet contains Methyldopa equivalent to 250mg anhydrous
methyldopa.
Excipients with known effect: Also contains lactose monohydrate and
sunset
yellow (E110).
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Film-coated Tablets
Yellow, circular, normal convex, film-coated tablets.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
In the treatment of hypertension.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Posology _
_Use in adults: _
_Initial dosage:_ Usually 250 mg two or three times a day, for two
days.
_Adjustment_: Usually adjusted at intervals of not less than two days,
until an adequate
response is obtained. The maximum recommended daily dosage is 3 g.
Many patients experience sedation for two or three days when therapy
with
methyldopa is started or when the dose is increased. When increasing
the dosage,
therefore, it may be desirable to increase the evening dose first.
Withdrawal of methyldopa is followed by return of hypertension,
usually within 48
hours. This is not complicated generally by an overshoot of blood
pressure.
_Patients with renal impairment: _
Methyldopa is largely excreted by the kidney, and patients with
impaired renal
function may respond to smaller doses.
_Other antihypertensives: _
Therapy with methyldopa may be initiated in most patients already on
treatment with
other antihypertensive agents by terminating these antihypertensive
medications
gradually, as required. Following such previous antihypertensive
therapy, methyldopa
should be limited to an initial dose of not more than 500 mg daily and
increased as
required at intervals of not less than two days.
When methyldopa is given to patients on other antihypertensives the
dose of these
agents may need to be adjusted to effect a smooth transition.
When 500 mg of methyldopa is added to 50 mg of hydrochlorothiazide,
the two
agents may be given together once daily.
_Paediatri